News|Articles|July 6, 2026

First Half 2026 Recap – Psychiatry

Fact checked by: Tim Smith

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

The first half of 2026 delivered significant regulatory and clinical momentum across psychiatry. The US Food & Drug Administration (FDA) expanded lumateperone (Caplyta) for schizophrenia relapse prevention, approved milsaperidone (Bysanti) for bipolar I disorder and schizophrenia, cleared ProlivRx as the first at-home neuromodulation device for major depressive disorder (MDD), and accepted centanafadine's NDA for priority review in ADHD.

Related to this article

October 5th, 2026

Q3 2026 Recap: Psychiatry News and Updates

Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.

October 2nd, 2026

5 Psychiatry Headlines You Missed in September 2026

Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.

October 8th, 2026

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

October 8th, 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

October 8th, 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

October 8th, 2026

Viaskin Peanut Patch FAQ: Where It Fits Beside Omalizumab and OIT

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.